BOSTON, Sept. 01, 2023 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe.
BOSTON, Sept. 01, 2023 (GLOBE NEWSWIRE) PepGen Inc. (NASDAQ:PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of